Metfogamma

Metformin Hydrochloride, the active ingredient in Metfogamma, is a biguanide presented as an oral tablet for oral use. It lowers blood glucose by improving insulin sensitivity and is indicated for the management of type 2 diabetes mellitus in adult patients.

GNH USA supplies Metfogamma as a licensed, GDP‑compliant international pharmaceutical product to hospitals, pharmacies and clinics worldwide, ensuring quality and regulatory conformity across EU and global markets. The company adheres to stringent manufacturing standards and provides reliable supply chain support for healthcare providers seeking consistent access to essential antidiabetic therapy.

Metfogamma, a biguanide antidiabetic, is used to improve glycemic control in disorders related to insulin resistance.

- Type 2 diabetes mellitus: improves blood glucose control and reduces HbA1c levels. - Impaired glucose tolerance: helps normalize fasting glucose and delay progression to diabetes. - Metabolic syndrome: contributes to weight management and enhances insulin sensitivity.

Metfogamma may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Nausea: transient feeling of sickness, often early in therapy. - Diarrhea: loose stools that may improve with dose adjustment. - Abdominal discomfort: cramping or pain in the stomach area. - Metallic taste: unusual taste sensation in the mouth.

Serious or Rare Side Effects: - Lactic acidosis: rare but life‑threatening buildup of lactate, requiring immediate medical attention. - Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hepatic dysfunction: signs of liver injury including jaundice or elevated enzymes. - Vitamin B12 deficiency: long‑term use may reduce B12 absorption leading to anemia.

When prescribing Metfogamma, clinicians should consider several safety measures to minimize risk. - Renal function: assess eGFR before initiation and monitor periodically. - Hepatic function: avoid use in patients with severe liver disease. - Lactic acidosis risk: discontinue if patient develops unexplained fatigue, dyspnea, or abdominal pain. - Pregnancy: use only if potential benefit justifies potential fetal risk. - Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Metfogamma can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Iodinated contrast agents: may precipitate lactic acidosis; suspend metformin before and after imaging. - Cimetidine: can increase metformin plasma concentrations. - Alcohol excess: heightens risk of lactic acidosis.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask hypoglycemia symptoms. - Diuretics: can affect renal clearance of metformin. - Corticosteroids: may raise blood glucose, requiring dose adjustment. - Thyroid hormones: may influence metabolic rate and glucose control.